The treatment of active gastric ulcers with KangFuXin Ye--a randomized controlled clinical trial

The effects of KangFuXin Ye on the ulcer healing and the quality of healing in the treatment of active gastric ulcer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016443

Enrollment

Unknown

Registered

2018-06-01

Start date

2018-06-11

Completion date

Unknown

Last updated

2018-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric ulcer

Interventions

group A:esomeprazole

group B:esomeprazole and KangFuXin Ye

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old male or female; 2. active gastric ulcer determined by endoscopy.

Exclusion criteria

Exclusion criteria: 1. anastomotic ulcer, pyloric obstruction, and frost like ulcer; 2. duodenal ulcer; 3. non-peptic ulcer,such as gastrinoma,gastric Crohn disease, gastric lymphoma; 4. suspected malignant gastric ulcer; 5. gastric ulcer with active bleeding,hospitalization is recommended; 6. women during pregnant or breast-feed stage; 7. severe heart, liver and renal insufficiency; 8. those who are allergic or those contraindications to the drugs used in this study; 9. those who are inadvisable to enter the study determined by researches.

Design outcomes

Primary

Measure	Time frame
gastric ulcer stage;the quality of ulcer healing;	—

Secondary

Measure	Time frame
H.pylori eradication;	—

Countries

China

Contacts

Public ContactPeng Yan

Liaocheng People's Hospital

yanplc@163.com+86 635 8272035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026